Consegna trials BreatheAssist in athletes

Respiratory and drug delivery company Consegna (ASX:CGP) has said a prototype of its nasal BreatheAssist technology was well received by athletes and trainers during a pilot study.

The trial involved 36 athletes and trainers using the BreatheAssist Sport prototype during three separate exercise sessions. The sessions included running, cycling, rowing and weight training.

Two thirds of participants felt they got more air into their lungs while using the device, 60% felt less fatigued during training than usual and close to half felt their breathing returned to normal more quickly.

The study also involved more qualitative measures - for example, 80% of respondents reported that they would buy BreatheAssist online and 77% believe that the technology will enable them to train at a higher intensity.

Consegna added that the results have provided the company with suggestions for improvements in sizing and comfort that can be used to help shape the final design.

“As we move closer to our Australian test market launch, these outcomes provide us with strong confidence and the clearest indicator yet of the potential for the BreatheAssist product to capture a share of the US$6.17 billion ($7.05 billion) global sport supplement market,” Consegna CEO Michael Johnson said.

BreatheAssist intranasal devices are designed to dilate the nostrils and/or deliver drugs. Consegna is also targeting markets including snoring management, sleep apnea and weight management.

Consegna shares were trading 9.52% higher at $0.023 as of around 1.30 pm on Thursday.